OneSource Specialty Pharma Ltd
OneSource Specialty Pharma Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
Get OneSource Specialty Pharma Ltd's next results in your feed
Guidance rank: #3 of 85 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
OneSource Specialty Pharma aims for $400 million in sales revenue by FY 2028, maintaining 38%-40% EBITDA margin. OneSource Specialty Pharma anticipates strong revenue growth, targeting $400 million by FY '28, with a 30% CAGR from FY '25 to '28.
From OneSource Specialty Pharma Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- OneSource Specialty Pharma aims for $400 million in sales revenue by FY 2028, maintaining 38%-40% EBITDA margin.
- Strong order book supports significant capacity expansion from 40 million to over 90 million units by December 2025.
- FY 2026 is a transition year with lumpy revenue due to regulatory approvals; stronger H2 expected, mirroring FY 2025 pattern.
- Customer forecasts and patent expiries guide capacity ramp-up; near full utilization expected as commercial launches increase.
- Anticipated launches of key products like Liraglutide, Teriparatide, and Semaglutide generics in FY 2026 across multiple markets.
- Market expansion driven by increased access in underserved regions (e.g., Brazil and Canada), with 4-12x potential volume growth.
2 more points from OneSource Specialty Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what OneSource Specialty Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- OneSource Specialty Pharma plans to invest over $100 million over the next couple of years to expand capacity and capabilities.
- Capacity is being increased from a rated 40 million to over 90 million by December 2025.
- Capacity additions are primarily in India, but the company is open to exploring expansion outside India, both organically and inorganically.
- Customer participation in capex is part of arrangements to secure capacity (e.g., take-or-pay contracts, reservation fees).
- The company is adding new capabilities, such as high-viscous pre-filled syringes, within its broader platform.
2 more points from OneSource Specialty Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what OneSource Specialty Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- OneSource Specialty Pharma has a strong and growing order book with around 50 ongoing drug-device combination (DDC) projects, including both fully delivered and in-execution.
- The order book is aligned with customers' forecasts and patent expiries over the next 2-3 years, supporting capacity ramp-up.
- The company is actively adding capacity, aiming to nearly double rated capacity from about 40 million to over 90 million by the end of 2025.
- Capacity expansions are primarily to serve ongoing Master Service Agreements (MSAs) and Customer-Specific Agreements (CSAs).
- Customers have provided take-or-pay contracts and long-term forecasts, ensuring secured capacity allocations.
2 more points from OneSource Specialty Pharma Ltd's call on order book
Create a free account to keep reading this call
OneSource Specialty Pharma Ltd — Quarterly revenue & net profit
OneSource Specialty Pharma Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 426 | 73 | +483.6% | 393 | +8.4% |
| Operating profit (EBITDA) | 183 | -3 | — | 142 | +28.9% |
| Operating margin | 43% | -3.8% | +46.8 pp | 36% | +7 pp |
| Profit before tax | 83 | -40 | — | -67 | — |
| Net profit (PAT) | 98 | -40 | — | -69 | — |
| EPS (₹) | 8.61 | — | — | -6.02 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹516 Cr, net profit ₹57 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What OneSource Specialty Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- 3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
OneSource Specialty Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were OneSource Specialty Pharma Ltd Q4 FY25 results?
OneSource Specialty Pharma aims for $400 million in sales revenue by FY 2028, maintaining 38%-40% EBITDA margin. OneSource Specialty Pharma anticipates strong revenue growth, targeting $400 million by FY '28, with a 30% CAGR from FY '25 to '28.
What is OneSource Specialty Pharma Ltd share price analysis?
OneSource Specialty Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹17,817 Cr. Investors should review the full earnings analysis for detailed insights.
Is OneSource Specialty Pharma Ltd planning capital expenditure?
OneSource Specialty Pharma plans to invest over $100 million over the next couple of years to expand capacity and capabilities.
Keep OneSource Specialty Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.